HRS-3005
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 11, 2026
Phase I Study of HRS-3005 in B-cell Malignancies
(clinicaltrials.gov)
- P1 | N=190 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Oncology
1 to 1
Of
1
Go to page
1